Hansa Biopharma AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HNSA.ST research report →
Companywww.hansabiopharma.com
Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that is in phase 3 clinical trial for use in sensitized kidney transplantations patients, as well as for anti-GBM antibody disease; and phase 2 clinical trial for antibody-mediated kidney transplant rejection and Guillain Barré syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy.
- CEO
- Renee Aguiar-Lucander
- IPO
- 2007
- Employees
- 138
- HQ
- Lund, SE
Price Chart
Valuation
- Market Cap
- $2.73B
- P/E
- -4.96
- P/S
- 14.31
- P/B
- -12.41
- EV/EBITDA
- -5.86
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 59.68%
- Op Margin
- -299.07%
- Net Margin
- -361.44%
- ROE
- 201.60%
- ROIC
- -59.99%
Growth & Income
- Revenue
- $222.26M · 29.74%
- Net Income
- $-529,252,000 · 34.44%
- EPS
- $-6.52 · 49.22%
- Op Income
- $-520,710,000
- FCF YoY
- 18.64%
Performance & Tape
- 52W High
- $42.98
- 52W Low
- $22.82
- 50D MA
- $29.54
- 200D MA
- $32.20
- Beta
- 1.50
- Avg Volume
- 402.28K
Get TickerSpark's AI analysis on HNSA.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our HNSA.ST Coverage
We haven't published any research on HNSA.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate HNSA.ST Report →